K. Albain

发表

Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction, and anxiety.

D. Hayes, S. Lo, P. Mumby, 2009 .

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

American S ociety o f C linical O ncology G uideline o n t he Role o f B isphosphonates i n B reast C ancer

B. Hillner, R. Chlebowski, J. Ingle, 2000 .

Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.

L. Pusztai, D. Yee, C. Yau, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)

E. Perez, V. Bramwell, K. Pritchard, 2007 .

A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342

Edward S. Kim, R. Herbst, K. Kelly, 2007 .

Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

G. Hortobagyi, R. Livingston, W. Barlow, 2008 .

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

E. Winer, L. Carey, W. Barry, 2013 .

Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342.

J. Crowley, R. Herbst, K. Kelly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

R. Peto, M. Piccart, S. Darby, 2012, Lancet.

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

G. Hortobagyi, L. Pusztai, W. Barlow, 2023, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

S. Loibl, J. Unger, M. Ceppi, 2018 .

Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection

D. Hayes, S. Lo, P. Mumby, 2007 .

American S ociety o f C linical O ncology 2 003 U pdate o n t he Role o f B isphosphonates a nd B one H ealth I ssues i n W omen With B reast C ancer

J. Cauley, B. Hillner, R. Chlebowski, 2003 .

ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer

M. Piccart, G. Hortobagyi, G. Sledge, 2005 .

Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626

S. Martino, R. Livingston, P. Ganz, 2001 .

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

OT1-03-01: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients (pts) with 1–3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2−Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007.

C. Moinpour, S. Ramsey, W. Barlow, 2011 .

SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.

G. Hortobagyi, C. Moinpour, S. Ramsey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.

G. Hortobagyi, S. Shak, W. Barlow, 2010 .

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

D. Cutter, P. Mcgale, C. Davies, 2012, The Lancet.